Vaxcyte Closes Offerings of Common Stock, Warrants, and Senior Notes

MT newswire2026/10/09 20:27

04:27 PM EDT, 10/09/2026 (MT Newswires) -- Vaxcyte (PCVX) is closing its public offerings of $1.15 billion of common stock and pre-funded warrants as well as convertible senior notes, it said late Friday. The company offered nearly 8.6 million common shares at $64 apiece and pre-funded warrants to purchase 400,000 shares at $63.999 per pre-funded warrant, according to a statement. Vaxcyte said it also offered $575 million of 1.5% convertible senior notes due 2032. The offering included the full exercise of overallotment options by the underwriters to buy up to 1.17 million additional shares and $75 million of the notes offered, according to the company. Net proceeds will be used to fund clinical development of Vaxcyte's pneumococcal vaccine programs, including VAX-31, manufacturing expansion, research and development, and general corporate purposes, the company said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.